Rubicon Research plans to raise ₹500 crore through a fresh issue for debt repayment and acquisitions, alongside an ₹877.5 crore offer for sale. The pharmaceutical company reported strong revenue and profit growth with margin expansion, boasting a higher RoNW than peers. However, high revenue concentration in the US and from top customers presents a risk.
Warning Signal? FIIs cut stake in 11 smallcap stocks in the last 3 quarters; prices crash up to 70%
Reliance Power’s shares declined as the Enforcement Directorate filed a chargesheet in a fake bank guarantee case, weighing on investor sentiment and drawing renewed attention